<DOC>
	<DOCNO>NCT02893488</DOCNO>
	<brief_summary>This open-label , randomize , crossover study healthy adult subject 5 treatment group 5 dose period . This study evaluate pharmacokinetic parameter relative bioavailability dispersible , fixed-dose combination ( FDC ) tablet TRIUMEQ™ ( [ abacavir , ABC ] / [ dolutegravir , DTG ] / [ lamivudine , 3TC ] ) disperse consume four different dose condition comparison oral dose TIVICAY™ ( DTG ) + EPZICOM™ ( ABC/3TC ) non-dispersible tablet administer fasted state . Approximately 20 subject randomize , one 5 treatment group . The total duration participation subject study approximately 10-11 week . It include screen visit within 30 day prior first dose study drug , five treatment period single dose study drug per treatment period follow visit within 7 10 day last dose . There also washout least 7 day dose treatment period . TRIUMEQ , EPZICOM , TIVICAY trademark GlaxoSmithKline group company .</brief_summary>
	<brief_title>Relative Bioavailability Study Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Inclusion Criteria Male female age 18 65 year age inclusive , time signing informed consent . Healthy determine investigator medically qualify designee base medical evaluation include medical history , physical examination , laboratory test cardiac evaluation ( history ECG ) . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; =50 kilogram ( kg ) males &gt; =45 kg female body mass index ( BMI ) within range 18.531.0 kg/m^2 ( inclusive ) . Male female Females nonreproductive potential define premenopausal female document tubal ligation , document hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion , hysterectomy , document bilateral oophorectomy , postmenopausal define 12 month spontaneous amenorrhea ( questionable case blood sample simultaneous follicle stimulate hormone [ FSH ] estradiol level consistent menopause ) . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . Female reproductive potential agrees follow one option list Modified List Highly Effective Methods Avoiding Pregnancy Females Reproductive Potential ( FRP ) 30 day prior first dose study medication 2 week dose study medication completion followup visit . The investigator responsible ensure subject understand properly use method contraception . Capable give sign informed consent include compliance requirement restriction list consent form protocol . Documentation subject negative human leukocyte antigen ( HLA ) B*5701 allele . Exclusion Criteria ALT bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . QT interval correct heart rate accord Fridericia 's formula ( QTcF ) &gt; 450 millisecond ( msec ) . The specific formula use determine eligibility discontinuation individual subject determine prior initiation study . In word , several different formula use calculate QTc individual subject low QTc value use include discontinue subject trial . Unable refrain use prescription ( i.e. , dofetilide ) nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 gram alcohol : 12 ounce ( 360 mL ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 1 month prior screen . History sensitivity study medication , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation . Creatinine clearance ( CrCL ) &lt; 60 mL/min Presence HBsAg , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . A positive prestudy drug/alcohol screen . A positive test HIV antibody . Where participation study would result donation blood blood product excess 500 mL within 56 day . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>dolutegravir</keyword>
	<keyword>abacavir</keyword>
	<keyword>relative bioavailability</keyword>
	<keyword>palatability</keyword>
	<keyword>GSK2619619</keyword>
	<keyword>palatability questionnaire</keyword>
	<keyword>lamivudine</keyword>
	<keyword>pediatric</keyword>
	<keyword>calcium</keyword>
	<keyword>dispersible tablet</keyword>
</DOC>